Douglas Lyles to Oncolytic Virotherapy
This is a "connection" page, showing publications Douglas Lyles has written about Oncolytic Virotherapy.
Connection Strength
1.791
-
Yu N, Puckett S, Antinozzi PA, Cramer SD, Lyles DS. Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer. J Virol. 2015 May; 89(10):5250-63.
Score: 0.517
-
Stewart JH, Ahmed M, Northrup SA, Willingham M, Lyles DS. Vesicular stomatitis virus as a treatment for colorectal cancer. Cancer Gene Ther. 2011 Dec; 18(12):837-49.
Score: 0.406
-
Cary ZD, Willingham MC, Lyles DS. Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo. J Virol. 2011 Jun; 85(12):5708-17.
Score: 0.394
-
Westcott MM, Liu J, Rajani K, D'Agostino R, Lyles DS, Porosnicu M. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis. J Virol. 2015 Aug; 89(15):7944-54.
Score: 0.131
-
Blackham AU, Northrup SA, Willingham M, Sirintrapun J, Russell GB, Lyles DS, Stewart JH. Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma. J Surg Res. 2014 Apr; 187(2):412-26.
Score: 0.118
-
Randle RW, Northrup SA, Sirintrapun SJ, Lyles DS, Stewart JH. Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors. Surgery. 2013 Dec; 154(6):1323-29; discussion 1329-30.
Score: 0.116
-
Blackham AU, Northrup SA, Willingham M, D'Agostino RB, Lyles DS, Stewart JH. Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus. Surgery. 2013 Mar; 153(3):333-43.
Score: 0.110